Navigation Links
Gastroenterologists Unlikely To Use Celltrion/Hospira's Infliximab Biosimilar Due To Lack Of Clinical Data In Inflammatory Bowel Disease
Date:9/30/2013

EXTON, Penn., Sept. 30, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the majority of surveyed gastroenterologists do not expect to prescribe an infliximab biosimilar, such as Celltrion's Remsima, in their Crohn's disease (CD) or ulcerative colitis (UC) patients that has not been clinically tested in inflammatory bowl diseases.

The Biosimilars Advisory Service report entitled Physician Perspectives on Pegylated IFN-a and TNF-a Inhibitors in Immune and Infectious Disease provides analysis of survey results from over 90 gastroenterologists, as well as more than 90 rheumatologists in the United States and Europe. The report finds that over 70 percent of surveyed gastroenterologists would not use biosimilar infliximab in CD or UC patients if the clinical trial had only been conducted in rheumatoid arthritis patients. Only a minority of survey respondents believe that indication extrapolation is an overall good idea.

The report also finds that surveyed rheumatologists are similarly cautious about indication extrapolation, but most biosimilars of TNF-alpha inhibitors under development are being studied in rheumatoid arthritis patients. This strategy by biosimilar manufacturers could help to alleviate rheumatologists' concerns about prescribing these biosimilar TNF-alpha inhibitors, but this study also reveals that rheumatologists would prefer a longer treatment duration and more patients to be included in biosimilar clinical trials compared with their gastroenterology counterparts. 

"The concept of indication extrapolation is particularly relevant to prescribers of TNF-alpha inhibitors because of the breadth of indications that these biologics are used in," said Biosimilars Research Director Kate Keeping. "The first biosimilar TNF-alpha inhibitor that gastroenterologists will have access to, Celltrion/Hospira's Inflectra (infliximab), has not been clinically tested in CD or UC patients, which will likely limit uptake in these patients, at least until direct clinical evidence is available."

The Biosimilars Advisory Service provides insight and analysis that is vital to successful business planning in the rapidly evolving biosimilars space. The service includes quarterly webinars detailing major developments, analyst insight addressing key market changes and opportunities, therapeutic area-specific primary research and forecasting modules.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Local Gastroenterologists First in South Florida to Offer Fecal Transplant
2. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
3. The Midwest Prepares to Tackle Gnats with an Unlikely Weapon
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
6. Novation Supports New Development in the U.S. Biosimilar Pharmaceuticals Market
7. ASBM Survey Reveals Key Safety Concern Associated with Biosimilar Naming; Urges Distinct Naming Requirement
8. Reliance Pharmaceuticals: Biosimilars Company Analysis
9. Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
10. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Enhanced Biosimilars and Personalized Medicine Initiatives for its Clients
11. Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2019)... ... October 08, 2019 , ... For many Americans, dental insurance is limited ... paid out of pocket. Yearly insurance payouts are generally capped at around $1,500—which doesn’t ... million people who are 65 or older. (Standard Medicare does not cover any dental ...
(Date:10/8/2019)... ... ... A free, interactive event highlighting innovations and ideas helping people with Parkinson’s live ... innovators and health experts, will display innovations that could help people with Parkinson’s disease ... on October 19 at the Coppertank Event Center in Austin, the event is co-hosted ...
(Date:10/8/2019)... ... 08, 2019 , ... Dr. Dorette Noorhasan offers a unique ... Fertility Doctor’s Fight for Motherhood (Brown Books Publishing Group), which releases today, October ... encourage, advise and support people who want to bring a new life into ...
Breaking Medicine Technology:
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... METAvivor Research ... breast cancer, announced the launch of its Stage IV Stampede campaign. The campaign will ... in Washington, DC that will include an advocacy boot camp, a march, a Die-In ...
(Date:10/8/2019)... ... October 08, 2019 , ... Dr. ... has recently attended an advanced Level III training in Cagliari, Italy, this past ... training took place September 16-19, 2019 at the Sardinia Dental Teaching Center and ...
(Date:10/8/2019)... , ... October 08, 2019 , ... ... headquartered in Irving, Texas, that exclusively serves premier oral and maxillofacial surgeons – ... oral and maxillofacial surgery practice with two locations near Knoxville, Tennessee. The partnership ...
(Date:10/8/2019)... ... 08, 2019 , ... Continuing its leading research on human ... Care4U™ 2’-FL, a DuPont product, beneficially changes microbiota composition and the production of ... microbiota and metabolite composition by 2’-FL were between the responses elicited by GOS ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... is pleased to announce the addition of Brenda Thomas, an industry professional with ... Account Manager for the Professional Services Plans dental team at Brown & Brown ...
Breaking Medicine News(10 mins):